HIVE Digital Technologies (TSX-V:HIVE, NASDAQ:HIVE) has reported record fiscal second quarter revenue, driven by the expansion of its Bitcoin mining operations and rising demand for its BUZZ high-performance computing (HPC) services.
Revenue was $87.3 million, up 285% from the same quarter last year and 91% sequentially, with adjusted EBITDA of $31.5 million.
Replenish Nutrients Holding Corp (CSE:ERTH, OTC:VVIVF) announced that it has entered into a three-year licensing agreement with Farmers Union Enterprises Inc to expand production of its patented SuperKS pellet fertilizer in the US.
Per the agreement, Farmers Union Enterprises (FUE) will have exclusive rights to manufacture and distribute SuperKS within its network across Minnesota, Montana, North Dakota, South Dakota and Wisconsin.
First Phosphate Corp. (CSE:PHOS, OTCQX:FRSPF) announced that it has completed an oversubscribed private placement to a strategic investor and other follow-on investors.
The company raised a total of $2.18 million through the issuance of 2.4 million flow-through shares at $0.90 per share, generating gross proceeds of approximately $2 million, and 177,666 hard dollar units at $0.90 per unit, adding about $160,000.
NanoViricides (NYSE-A:NNVC) is advancing its broad-spectrum antiviral NV-387, backed by new financing that strengthens its balance sheet and supports regulatory progress toward Phase II trials for monkeypox in Central Africa.
In its quarterly report for the quarter ended September 30, 2025, the clinical-stage biotech company said NV-387 is engineered to resist viral escape.
Millennial Potash Corp (TSX-V:MLP, OTCQB:MLPNF) reported a major upgrade to the mineral resource estimate (MRE) for the northern area of its Banio potash project in Gabon, including a large maiden Measured resource that company leadership said would underpin a forthcoming feasibility study.
The updated MRE outlines 648 million tonnes of Measured carnallitite resources, a type of potash-bearing rock used to produce potassium fertilizer, grading 15.7% KCl, the first time the project has reported a Measured category.
Algernon Health (CSE:AGN, OTCQB:AGNPF) said on Monday it has signed a strategic business and investment agreement with US-based American Molecular Imaging (AMI) to provide exclusive radiology reading services for its planned network of brain-focused PET neuroimaging clinics in the US.
Algernon said the facilities, slated to begin opening in early 2026, will be the first dedicated brain-optimized PET neuroimaging clinics in the country, aimed at early detection of Alzheimer’s disease as well as other dementias, epilepsy, neuro-oncology and movement disorders.
Trust Stamp Inc (NASDAQ:IDAI, EURONEXT:AIID) has reported increased net recognized revenue and reduced its operating expenses in the third quarter as it has expanded its customer base.
Net recognized revenue for the third quarter was $0.87 million, up 71% from $0.51 million in the same period of 2024.
Medicus Pharma (NASDAQ:MDCX) said on Monday it has applied for a US Food and Drug Administration Commissioner's National Priority Voucher (CNPV) to accelerate review of SkinJect, its investigational microneedle patch designed to non-invasively treat basal cell carcinoma (BCC).
The application includes a Statement of Interest outlining how SkinJect’s Doxorubicin Microneedle Array (D-MNA) aligns with the FDA’s national priorities, which focus on improving cancer care access, affordability and options for patients with rare diseases, the company said.
IXICO PLC (LSE:IXI, OTC:PHYOF) shares jumped 5% to 11.28p after the neuroscience analytics specialist landed a four-year contract worth more than £3.5 million to support a global phase III trial in Huntington’s Disease.
The London-based group will provide imaging services for the study under a deal with a major pharmaceutical company. Phase III trials are the final and most expensive stage before a drugmaker seeks regulatory approval, making this a commercially meaningful win for IXICO.
Eden Research PLC (AIM:EDEN, OTCQB:EDNSF) shares have pared some of their early gains but remain up 3% at 2.27p after the biopesticides group confirmed that Italy has granted another temporary authorisation for its Ecovelex seed treatment ahead of the 2026 maize season.
The approval, issued under EU Regulation 1107/2009, gives farmers continued access to one of the few bird-repellent treatments still available following the phase-out of older chemical options in the EU and UK.
OptiBiotix Health PLC (AIM:OPTI, OTC:OPBXF) shares traded higher on Monday morning, after it announced it has received a first order from a well-known European weight-management company.
It marks the first commercial step under an agreement signed in August, the company highlighted.
Pensana PLC (LSE:PRE, OTC:PNSPF) opened Monday's trading sharply higher after it announced a new drilling and metallurgical testwork programme at its Longonjo rare-earth project in Angola
Its goal is to increase the project's current 313-million-tonne Mineral Resource Estimate to more than one billion tonnes, the company said in its statement.
KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF) says it is on course to break ground at its Tulu Kapi project by the end of next year, marking what could be a turning point for Ethiopia’s emerging mining sector.
The company confirmed that its full development plan for the high-grade gold deposit has now been agreed by the project syndicate, clearing the way for construction once the remaining financial steps are completed.
IXICO PLC (LSE:IXI, OTC:PHYOF) has secured a contract worth more than £3.5 million to support a major phase III clinical trial in Huntington’s Disease, marking a significant commercial step for the neuroscience data specialist.
The London-based group said the four-year agreement, signed with a global pharmaceutical company, will see it provide imaging services for the worldwide study.
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has released new 30-day clinical results for its biomimetic DurAVR® transcatheter heart valve, reporting encouraging safety and performance outcomes in 100 severe aortic stenosis patients with small aortic annuli — a cohort where prosthesis-patient mismatch is more common.
The data, presented overnight at the PCR London Valves conference and published simultaneously in EuroIntervention, build on the company’s earlier findings from feasibility studies and the ongoing EMBARK program. The cohort represents around 20% of the planned DurAVR® enrolment for the all-comers randomised arm of PARADIGM, Anteris’ recently launched pivotal global trial.
Cyprium Metals Ltd (ASX:CYM, OTC:CYPMF) has cleared the final administrative hurdle for the restart of cathode operations at its Nifty Copper Complex in the Paterson region of Western Australia. The Western Australia Department of Energy and Economic Diversification has approved the company’s Notice to Proceed, building on earlier regulatory submissions made under the State Agreement governing Nifty.
The restart forms part of Cyprium’s phased redevelopment strategy for Nifty and will initially focus on recovering copper from existing above-ground leach pads.
Race Oncology Ltd (ASX:RAC, OTC:RAONF) has unveiled two new clinical programs for its lead asset RC220, expanding into acute myeloid leukaemia (AML) and EGFR-mutated non-small cell lung cancer (NSCLC) as the company looks to progress multiple late-stage opportunities in parallel.
The initiatives build on recent discoveries around RC220’s molecular mechanism and are designed to create a streamlined regulatory path while targeting major oncology markets where treatment resistance remains a critical challenge.